Allergan and Gedeon Richter Plc. to Present Data on VRAYLAR (cariprazine) at the American College of Neuropsychopharmacology (ACNP) Annual Meeting

Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced they will present data on VRAYLAR (cariprazine) in patients with schizophrenia during the 54th American College of Neuropsychopharmacology (ACNP) Annual Meeting in Hollywood Florida, to be held December 6 – 10, 2015. Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO Data to be presented include additional analyses of cariprazine for the potential treatment of predominant negative symptoms in patients with schizophrenia. Also presented will be data investigating the metabolic safety profile of cariprazine and its impact on long-term schizophrenia relapse prevention. Data Blitz oral presentation given by Rene KahnMonday, December 7, 2015, 11:30 a.m.-1:30 p.m. ET, Oral Presentation Cariprazine as Monotherapy for the Treatment of Predominant Negative Symptoms of Patients with Schizophrenia: A Double-Blind, Active Comparator-Controlled Trial (poster M206) authored by Debelle, M., Nemeth, G., Szalai, E., Szatmari, B., Harsanyi, J., Barabassy, A., Laszlovszky, I., Durgam, S., Fleischhacker, W.W., Kahn, R.PostersMonday, December 7, 2015, 5:30-7:30 p.m. ETCariprazine as Monotherapy for the Treatment of Predominant Negative Symptoms of Patients with Schizophrenia: A Double-Blind, Active Comparator-Controlled Trial (poster M206) authored by Debelle, M., Nemeth, G., Szalai, E., Szatmari, B., Harsanyi, J., Barabassy, A., Laszlovszky, I., Durgam, S., Fleischhacker, W.W., Kahn, R. Cariprazine for Negative Symptoms of Schizophrenia: Pooled Post Hoc Analysis of 2 Randomized, Double-Blind, Placebo- and Active-Controlled Trials (poster M204), authored by Earley, W., Durgam, S., Debelle, M., Laszlovszky, I., Lu, K., Nasrallah, H. Metabolic Safety of Cariprazine in Patients with Schizophrenia (poster M156) authored by Marder, S., Zukin, S., Lu, K., Debelle, M., Durgam, S. Tuesday, December 8, 2015, 5:30-7:30 p.m. ET Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: Additional Analysis From a Randomized, Double-Blind, Placebo-Controlled Trial (poster T170), authored by Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Edwards, J., Nasrallah, H., Fleischhacker, W.W.